Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19

Frontiers in Medicine

article

Gaber El-Saber Batiha¹  Achyut Adhikari²  Ishan Pandey³  Sara T. Elazab⁴  Kannan R. R. Rengasamy⁵  Natália Cruz-Martins⁶  Helal F. Hetta⁹  Marwa A. Zayed¹  Aya A. Awad¹  Hazem M. Shaheen¹  Suleiman Mustapha^1,10  Oscar Herrera-Calderon^1,11  Jorge Pamplona Pagnossa^1,12  Abdelazeem M. Algammal^1,13  Muhammad Zahoor^1,14 

[1] Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University;Central Department of Chemistry, Tribhuwan University;Department of Pathology, Motilal Nehru Medical College;Department of Pharmacology, Faculty of Veterinary Medicine, Mansoura University;Green Biotechnologies Research Centre of Excellence, University of Limpopo;Faculty of Medicine, University of Porto;Institute for Research and Innovation in Health (i3S), University of Porto;Laboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto;Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University;Department of Crop Protection, University of Ilorin;Department of Pharmacology, Faculty of Pharmacy and Biochemistry, Universidad Nacional Mayor de San Marcos;Biological Sciences Department, Federal University of Lavras (UFLA);Department of Bacteriology, Faculty of Veterinary Medicine, Suez Canal University;Department of Biochemistry, University of Malakand

关键词: COVID-19;    SARS-CoV-2 infection;    macrolides;    azithromycin;    efficacy;   

DOI  :  10.3389/fmed.2021.642313

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Macrolides (e.g., erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic. Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities. Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment. Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release. In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19.

【 授权许可】

CC BY